A Phase 4 interventional study of simvastatin (+) ezetimibe and Comparator: atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 36th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 31 in phase 4, and was the 23rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 229 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 48th largest by enrollment of the 81 interventional ones that give a count, is one of 7 that started in 2006, is one of 19 in phase 4, and was the 36th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: simvastatin (+) ezetimibe
Drug: Comparator: atorvastatin
Drug pages: Ezetimibe · Simvastatin
simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
Also known as: MK0653A, Vytorin®
atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
Also known as: Lipitor®
Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment
Primary objective is to evaluate the proportion of patients achieving LDL-C target \<100 mg/dl recommend in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) after 6 weeks of treatment(vytorin 10/20 vs. atorvastatin 10 mg)
Time frame: After 6 weeks of treatment
Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment
If patients didn't achieve LDL-C \<100 mg/dl after 6 weeks of treatment, they received the double dosage of study drug for the next 6 weeks (vytorin 10/40 or atorvastatin 20 mg) and If achieved LDL-C \< 100 mg/dl, they received the same dosage of study drug for the next 6 weeks.
Time frame: After 12 weeks of the treatment
Patient were recruited between September 2006 and May 2008.
| Milestone | Vytorin | Atorvastatin |
|---|---|---|
| Started | 118 | 111 |
| Completed | 101 | 99 |
| Not completed | 17 | 12 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Protocol violation | 7 | 3 |
| Withdrew: Withdrawal by subject | 9 | 8 |
| Milestone | Vytorin | Atorvastatin |
|---|---|---|
| Started | 35 | 34 |
| Completed | 29 | 28 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
Primary objective is to evaluate the proportion of patients achieving LDL-C target \<100 mg/dl recommend in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) after 6 weeks of treatment(vytorin 10/20 vs. atorvastatin 10 mg)
| Participants | Vytorin | Atorvastatin |
|---|---|---|
| Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment | 89 | 63 |
If patients didn't achieve LDL-C \<100 mg/dl after 6 weeks of treatment, they received the double dosage of study drug for the next 6 weeks (vytorin 10/40 or atorvastatin 20 mg) and If achieved LDL-C \< 100 mg/dl, they received the same dosage of study drug for the next 6 weeks.
| Participants | Vytorin | Atorvastatin |
|---|---|---|
| Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment | 85 | 63 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vytorin | — | 0/108 (0%) | 19/108 (17.6%) |
| Atorvastatin | — | 5/103 (4.9%) | 22/103 (21.4%) |
| Event | Vytorin | Atorvastatin |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/108 | 3/103 |
| Cardiogenic shockCardiac disorders | 0/108 | 1/103 |
| Ventricular tachycardiaCardiac disorders | 0/108 | 1/103 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/108 | 1/103 |
| CholelithiasisHepatobiliary disorders | 0/108 | 1/103 |
| Thrombosis in deviceInjury, poisoning and procedural complications | 0/108 | 1/103 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/108 | 1/103 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/108 | 1/103 |
| Event | Vytorin | Atorvastatin |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/108 | 0/103 |
| NasopharyngitisInfections and infestations | 1/108 | 2/103 |
| Generalized oedemaGeneral disorders | 0/108 | 2/103 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/108 | 2/103 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/108 | 2/103 |
| Blood creatine phosphokinase increasedInvestigations | 1/108 | 2/103 |
| HeadacheInfections and infestations | 2/108 | 1/103 |
| Transaminases increasedInvestigations | 2/108 | 0/103 |
| CystitisInfections and infestations | 0/108 | 1/103 |
| DysphasiaNervous system disorders | 0/108 | 1/103 |
| Age, Continuous(years) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 60.89 ± 9.28 | 61.74 ± 9.94 | 61.30 ± 9.59 |
| Sex: Female, Male(Participants) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Female | 57 | 53 | 110 |
| Male | 61 | 58 | 119 |
| Baseline Low Density Lipoprotein-Cholesterol (LDL-C) allocation strata(Participants) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| LDL-C 130-159mg/dl | 64 | 61 | 125 |
| LDL-C 160-189mg/dl | 38 | 31 | 69 |
| LDL-C >=190mg/dl | 16 | 18 | 34 |
| LDL-C <130mg/dl | 0 | 1 | 1 |
| Baseline values for Apolipoprotein B (Apo B)(mg/dL) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 113.23 ± 30.97 | 110.63 ± 31.63 | 111.97 ± 31.25 |
| Baseline values for High-Density Lipoprotein Cholesterol (HDL-C)(mg/dL) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 48.23 ± 10.25 | 48.9 ± 13.01 | 48.55 ± 11.65 |
| Baseline values for LDL-C:HDL-C(Ratio) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 3.54 ± 1.13 | 3.54 ± 1.04 | 3.54 ± 1.08 |
| Baseline values for Low-Density Lipoprotein Cholesterol(LDL-C)(mg/dL) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 164.11 ± 33.52 | 162.56 ± 26.75 | 163.36 ± 30.37 |
| Baseline values for Non HDL-C(mg/dL) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 191.54 ± 38.25 | 190.72 ± 31.11 | 191.14 ± 34.88 |
6 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin